Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

WuXi AppTec Co., Ltd. (603259.SS)

Shanghai - Shanghai Delayed Price. Currency in CNY
Add to watchlist
91.94+0.94 (+1.03%)
At close: 03:00PM CST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close91.00
Open91.15
Bid91.94 x 0
Ask91.95 x 0
Day's Range91.02 - 92.40
52 Week Range81.82 - 158.88
Volume21,358,280
Avg. Volume29,180,287
Market Cap266.356B
Beta (5Y Monthly)0.70
PE Ratio (TTM)65.21
EPS (TTM)1.41
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & Yield0.52 (0.54%)
Ex-Dividend DateJun 09, 2022
1y Target Est158.47
  • PR Newswire

    WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

    WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware. First announced in June 2021, this site will be WuXi STA's second facility in the United States, offering expanded capacity and greater flexibility to meet the needs of customers in the U.S. and around the world.

  • PR Newswire

    WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology

    WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen"). Under this agreement, WuXi ATU will license to Janssen its TESSA™ technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems. Janssen will also have access to work on WuXi ATU's proprietar

  • PR Newswire

    WuXi AppTec Reports Record First-Half Results in 2022

    WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the first half of the year ending June 30, 2022 ("Reporting Period").

Advertisement
Advertisement